Damien Stevens, MD
Pulmonary Disease · Kansas City, KSNPI 1548262322
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,882 of the $2,565 with a category attached, or 73.4%. Inspire Medical Systems, Inc. accounts for 79.6% of it on its own, with 14 other manufacturers making up the rest. That places this record below the midpoint for pulmonary disease clinicians in KS, where the typical reported total is $1,991.
Across 54 payments — averaging $47.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- GSK$85
- Boehringer Ingelheim$76
- AstraZeneca$65
- Harmony Biosciences LLC$56
- Lilly USA, LLC$39
- plus $203 from 9 others
Across 65 payments — averaging $3162.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$120K
- Inspire Medical Systems, Inc.$51K
- Alkermes, Inc.$35K
What the payments were for
- Travel & lodging$68327%
- Food & beverage$1,88273%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 28 | $2,042 |
| GSK | 4 | $85 |
| Boehringer Ingelheim | 3 | $76 |
| AstraZeneca | 3 | $65 |
| Harmony Biosciences LLC | 3 | $56 |
| Lilly USA, LLC | 2 | $39 |
| Mylan Specialty L.p. | 2 | $36 |
| Viatris Specialty LLC | 2 | $36 |
| Grifols USA, LLC | 1 | $24 |
| Breas Medical, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,565 in reported general payments places this provider in the 50th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $231,326 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $230,598 |
| OfevNintedanib Esylate | 13 | $180,678 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $85,072 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 81 | $42,054 |
| Spiriva RespimatTiotropium Bromide | 34 | $26,637 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $19,973 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $14,639 |
| NeuproRotigotine | 13 | $10,315 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $8,577 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,500 |
| Armodafinil | 29 | $3,061 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,019 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $2,273 |
| Ventolin HfaAlbuterol Sulfate | 31 | $1,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $76 | $249,369128 claims |
| Grifols USA, LLCProlastin C | $24 | $231,32614 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $85 | $119,683181 claims |
| AstraZenecaSymbicort | $65 | $8,57727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Kansas City
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
- Heath LathamKansas City$15K
- Kyle BrownbackKansas City$15K
- Michelle HomanKansas City$8K
- Aman KhanKansas City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.